z-logo
Premium
Topiramate in Lennox–Gastaut Syndrome: Open‐Label Treatment of Patients Completing a Randomized Controlled Trial
Author(s) -
Glauser Tracy A.,
Levisohn Paul M.,
Ritter Frank,
Sachdeo Rǎjesh C.
Publication year - 2000
Publication title -
epilepsia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.687
H-Index - 191
eISSN - 1528-1167
pISSN - 0013-9580
DOI - 10.1111/j.1528-1157.2000.tb02179.x
Subject(s) - lennox–gastaut syndrome , topiramate , medicine , dose , concomitant , placebo , randomized controlled trial , open label , randomization , anesthesia , epilepsy , surgery , psychiatry , alternative medicine , pathology
Summary: Purpose : The response to topiramate (TPM) as long‐term adjunctive therapy was evaluated in patients with Lennox‐Gastaut syndrome (LGS) in a long‐term, open‐label extension to a double‐blind, placebo‐controlled trial. Methods : In 97 patients with LGS (mean age, 11 years), dosages of TPM and concomitant antiepileptic drugs (AEDs) were adjusted to optimal clinical response (mean TPM dosage, 10 mg/kg/day). Results : For those patients who had completed 6 months of TPM therapy, drop attacks were reduced ges;50% in 55% of patients; 15% of patients had no drop attacks for ges;6 months at the last visit. After treatment up to 3 + years, 71% of patients who started open‐label TPM were continuing therapy at the last visit. Conclusions : During long‐term therapy, TPM is effective and well tolerated in controlling the treatment‐resistant drop attacks and seizures associated with LGS.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here